181 related articles for article (PubMed ID: 23373454)
1. Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th annual Frye-Halloran Brain Tumor Symposium.
Jones PS; Dunn GP; Barker FG; Curry WT; Hochberg FH; Cahill DP
Neurosurg Focus; 2013 Feb; 34(2):E9. PubMed ID: 23373454
[TBL] [Abstract][Full Text] [Related]
2. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
3. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management.
Sturm D; Pfister SM; Jones DTW
J Clin Oncol; 2017 Jul; 35(21):2370-2377. PubMed ID: 28640698
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetics of gliomas.
Appin CL; Brat DJ
Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
[TBL] [Abstract][Full Text] [Related]
5. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
[TBL] [Abstract][Full Text] [Related]
6. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
7. Low Grade Gliomas in Children.
Chalil A; Ramaswamy V
J Child Neurol; 2016 Mar; 31(4):517-22. PubMed ID: 26286938
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and prognosis of gliomas--current prospects of molecular diagnostics].
Haapasalo J; Hyartt A; Salmi M; Nordfors K; Lahtela SL; Kähkönen M; Helén P; Haapasalo H
Duodecim; 2014; 130(9):893-901. PubMed ID: 24881141
[TBL] [Abstract][Full Text] [Related]
9. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
10. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
11. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
12. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
Hargrave D
Br J Neurosurg; 2009 Aug; 23(4):351-63. PubMed ID: 19637006
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnostics of gliomas: the clinical perspective.
Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
[TBL] [Abstract][Full Text] [Related]
14. Low-grade glioma.
Kumthekar P; Raizer J; Singh S
Cancer Treat Res; 2015; 163():75-87. PubMed ID: 25468226
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
[TBL] [Abstract][Full Text] [Related]
16. The molecular biology of WHO grade II gliomas.
Marko NF; Weil RJ
Neurosurg Focus; 2013 Feb; 34(2):E1. PubMed ID: 23373446
[TBL] [Abstract][Full Text] [Related]
17. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
18. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
19. Input of molecular analysis in medical management of primary brain tumor patients.
Idbaih A; Duran-Peña A; Bonnet C; Ducray F
Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
[TBL] [Abstract][Full Text] [Related]
20. Advances in circular RNAs and their role in glioma (Review).
Zhang Y; Lin X; Geng X; Shi L; Li Q; Liu F; Fang C; Wang H
Int J Oncol; 2020 Jul; 57(1):67-79. PubMed ID: 32319596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
